Financial Data and Key Metrics Changes - Mativ's full year 2025 net sales were just under $2 billion, up 2.5% organically and modestly on a reported basis compared to the prior year [17] - Adjusted EBITDA for 2025 was $225 million, up 3% year-over-year, with Q4 Adjusted EBITDA increasing 19% to $53.5 million [18][22] - Free cash flow reached a record $94 million in 2025, more than doubling the previous year's result [22][23] Business Line Data and Key Metrics Changes - Filtration and Advanced Materials (FAM) segment net sales were up over 5% year-over-year, with adjusted EBITDA increasing by 26% [19][20] - Sustainable & Adhesive Solutions (SAS) segment sales were largely flat year-over-year on an organic basis, with adjusted EBITDA increasing by more than 8% [20][21] Market Data and Key Metrics Changes - The company faced headwinds in certain markets, particularly in automotive labels and release liners in Europe, impacting the SAS segment [33][49] - Despite challenges, FAM segment showed growth in transportation and industrial filtration, indicating resilience in specific market categories [35][56] Company Strategy and Development Direction - Mativ's strategy focuses on three pillars: enhancing commercial excellence, strengthening the balance sheet, and optimizing the portfolio [6][10] - The company aims to leverage AI as a foundational enterprise capability to drive productivity and operational improvements [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a complex macroeconomic environment with dynamic trade movements and geopolitical instability, emphasizing the need for agility [12][28] - For 2026, the company anticipates continued focus on cost-saving initiatives, with expected savings of $15 million to $20 million [27] Other Important Information - Mativ reduced net debt by over $60 million in 2025, ending the year with a net leverage ratio of 4.2 times [23][40] - The company plans to invest $45 million in capital expenditures in 2026, split between growth and efficiency projects [25] Q&A Session Summary Question: Details on headwinds within SAS and potential catalysts for improvement - Management noted weakness in automotive tapes and release liners, but expressed optimism about growth opportunities in other categories and regions [33][34] Question: Sustainability of momentum in FAM segment - Management highlighted ongoing investments and improvements in the FAM segment, expecting continued growth despite market challenges [35][36] Question: Free cash flow expectations for 2026 - Management indicated a small decline in free cash flow from 2025's record levels, primarily due to funding growth initiatives [37][38] Question: Guidance for Q1 and market conditions - Management expects low single-digit volume growth in Q1, with EBITDA growth of 15%-20% despite soft demand [45][52] Question: Commercial pipeline performance relative to market - Management emphasized a focused approach to the commercial pipeline, with strong customer collaboration and improved operational metrics [56]

Core Viewpoint - Kodak faces significant financial challenges due to a lack of committed financing or available liquidity to repay a $500 million debt, raising serious doubts about its ability to continue operations [1][2] Financial Performance - Kodak's stock price plummeted over 25% on December 12, and further declined by 21% to $5.43 per share on the morning of December 13 [2] - The company plans to stop pension payments to generate cash for debt repayment and expresses confidence in repaying a substantial portion of the debt before maturity [2] Historical Context - Founded in 1892, Kodak once dominated the film camera market, holding 90% of the U.S. film market and 85% of the camera market in the 1970s, but has struggled since the rise of digital cameras [2] - Kodak filed for bankruptcy restructuring in 2012 and returned to the New York Stock Exchange in September 2013, expanding its business into commercial printing, packaging, and film production [2] Future Outlook - The company received a $765 million loan from the U.S. government in 2020 to enter the non-patent drug raw materials manufacturing sector [2] - Investors are questioning whether Kodak can navigate this debt crisis successfully or if it is nearing the end of its operational history [2]